Royal Bank Of Canada Tricida, Inc. Transaction History

Royal Bank Of Canada

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.14 - $12.49 $51 - $4,596	-368 Reduced 8.9%	3,767 $0
Q3 2022 Nov 14, 2022	BUY	$8.51 - $13.6 $29,342 - $46,892	3,448 Added 501.89%	4,135 $43,000
Q2 2022 Aug 15, 2022	SELL	$7.31 - $11.85 $44,298 - $71,811	-6,060 Reduced 89.82%	687 $7,000
Q1 2022 May 16, 2022	BUY	$7.35 - $10.63 $49,590 - $71,720	6,747 New	6,747 $55,000
Q3 2021 Nov 15, 2021	SELL	$3.56 - $4.64 $22,079 - $28,777	-6,202 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$3.95 - $5.41 $24,497 - $33,552	6,202 New	6,202 $27,000

30K

124K

46.5K

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.